Autoimmune diseases
a global public
Healthcare Issue
with unmet medical needs

The number of patients affected by autoimmune diseases is increasing worldwide. The treatment of autoimmune diseases is costly and  a serious concern to healthcare system.

Kinoid® technology:
An innovative
therapeutic Approach

Our Kinoid®  technology is an alternative to monoclonal antibodies.

Our ambition:
to develop accessible treatments

Our goal is to provide patients with less costly, more convenient and safe treatments, without hospitalization.

About Neovacs

Neovacs is a French biotech company focused on the development of Kinoids®, therapeutic vaccines for the treatment of autoimmune, inflammatory diseases, allergies and cancer.

Discover our Kinoids®

Therapeutic vaccines to treat several chronic diseases:

IFN Kinoide
and LUPUS

Lupus is a chronic autoimmune disease, which can affect several organs. Currently in phase IIb clinical study in US, EU, Asia and South-America.

show more

IFN KINOID AND DERMATOMYOSITIS

Dermatomyositis is an orphan disease which can affect skin and muscles. Currently in phase IIa clinical study in EU.

show more

IFN KINOID AND TYPE I DIABETES

This disease is characterized by a destruction of the pancreas, its prevalence has increased 3 to 4% per year over the past two decades. Currently in preclinical Proof of concept stage.
show more

VEGF KINOID
AND CANCERS

Preclinical stage ongoing in collaboration with the Sunnybrook Research Institute of Toronto, Canada.

show more

IL-4 /IL-13 KINOID AND ALLERGIES

Neovacs’ technology has the potential to treat patients suffering from environmental and food allergies.

show more

Applying vaccine technology to treat chronic diseases

To better understand Neovacs’ Kinoid® technology, we invite you to watch this video.

More details

Why should you invest in Neovacs ?

go to the investors section

News

Neovacs to Give Update on Potential Lupus...

Neovacs to Give Update on Potential Lupus Vaccine, Now in Phase 2 Trial, at Conference click to the link to...

LupusNewsToday_black-290

Neovacs announces FDA approval

Healio Rheumatology May 2, 2016   Neovacs recently received FDA investigational new drug approval to...

helio

The Balancing Act TV- Understanding Lupus...

Today, biotech experts at the French medical research company, Neovacs, are on the brink of a true...

batv

ITW WITH TWO KEY PEOPLE OF THE FIGHT AGAINST...

Lupus is one of the most common rare disease and affects more than 5 million people worldwide.   This...

logoWEBCOUL1

Follow us on Twitter

Second clinical trial approved by the #FDA for #Neovacs' lead product candidate $ALNEV https://t.co/rbFfnbt5Wy

deuxième essai clinique avec le produit phare de #Neovacs autorisé par la #FDA aux États-Unis https://t.co/MyKiE127JF

#Neovacs Announces Positive IDSMB Review for Phase IIb Clinical Trial of IFNα Kinoid in Lupus https://t.co/T21w3jXX6c

L'iDSMB confirme le bon déroulement de l’essai clinique de phase IIb dans le #lupus avec l’IFNαKinoïde https://t.co/kZE0uYKXRP

Load More...